Rev. 8/13/2026

75N98026Q00996 - STATEMENT OF WORK

1.0 TITLE

Production of ChAdOx-1 and MVA expressing mouse gp70

2.0 BACKGROUND

Glioblastoma, a high-grade primary brain tumor, is one of the most aggressive and devastating cancers. Despite intensive treatment, including surgical resection, chemotherapy, and radiation therapy, the median survival remains less than 14 months, and the 5-year survival rate is below 10%.

There is a critical need for new therapeutic approaches.

Immunotherapy has transformed cancer treatment and has been approved for more than 30 cancer types, particularly for patients whose disease is refractory to conventional therapies. However, effective immunotherapies for primary brain tumors, including glioblastoma, remain limited.

We have developed a viral vector-based cancer vaccine using a combination of chimpanzee adenovirus (ChAdOx-1) and modified vaccinia Ankara (MVA) vectors in syngeneic orthotopic mouse glioblastoma models. This approach significantly prolonged survival in tumor-bearing animals by inducing a robust population of tumor antigen-specific CD8+ T cells in the brain. These T cells were sufficient to mediate the protective effects of the vaccine.

Based on these findings, we will evaluate the efficacy of this vaccine strategy in preventing brain metastases of breast cancer, an area of significant unmet clinical need. To support this work, it is necessary to develop viral vectors expressing the mouse tumor antigen gp70 in combination with the mouse class II major histocompatibility complex invariant chain (Ii).

3.0 OBJECTIVES

The primary objective of this project is to develop ChAdOx-1 and MVA viral vectors expressing the mouse tumor antigen gp70 in combination with the mouse class II major histocompatibility complex invariant chain (Ii).

4.0 SCOPE

The scope of this project includes the following:

1. Design and construction of a codon-optimized gene expression cassette encoding mouse gp70 and the mouse class II major histocompatibility complex invariant chain (Ii) for expression in mouse cells.

2. Production of a ChAdOx-1 viral vector encoding the gene construct.

3. Production of an MVA viral vector encoding the same gene construct.

4.1 TECHNICAL REQUIREMENTS

The Contractor shall perform the following tasks:

4.1.1 Project Management Plan

The Contractor shall develop and submit a project management plan that includes the overall project timeline, key milestones, and a description of the approach to complete all required tasks.

4.1.2 Gene Construct Design

The Contractor shall design and generate a codon-optimized gene construct encoding mouse gp70 and mouse class II MHC invariant chain (Ii), suitable for expression in mouse cells and compatible with viral vector systems.

4.1.3 ChAdOx-1 Vector Production

The Contractor shall produce a chimpanzee adenovirus (ChAdOx-1) viral vector encoding the gene construct. The vector shall be suitable for in vivo experimental use.

4.1.4 MVA Vector Production

The Contractor shall produce a modified vaccinia Ankara (MVA) viral vector encoding the same gene construct. The vector shall be suitable for in vivo experimental use.

4.3 PERSONNEL QUALIFICATIONS

The Contractor shall meet the following minimum qualifications:

• Demonstrated experience in designing codon-optimized gene constructs for viral vector applications

• Proven capability to produce chimpanzee adenovirus (ChAdOx-1) vectors

• Proven capability to produce modified vaccinia Ankara (MVA) viral vectors

• Ability to perform work in an efficient, reliable, and professional manner

4.3 SPECIAL ORDER REQUIREMENTS

N/A

5.0 TYPE OF ORDER

This is a Firm Fixed-Price Purchase Order.

6.0 PERIOD OF PERFORMANCE

The period of performance shall be 6 months from the date of award.

7.0 PLACE OF PERFORMANCE

All work shall be performed at the Contractor’s facility.

8.0 CONTRACTING OFFICERS REPRESENATIVE/TECHNICAL POINT OF CONTACT

All work delivered to the Contracting Officers Representative (COR) and Technical Point of Contact

(TPOC) will be deemed to have been accepted upon written confirmation of acceptance by the

COR/TPOC. The COR/TPOC’s approval or revision of the work delivered shall be within the general scope of work for the Purchase Order.

The following individual shall be the COR for this task order:

Alan Peigh

Office of Management (OA), National Cancer Institute (NCI)

National Institutes of Health (NIH)

Building 1050, Room 211

1050 Stark Street

Frederick, MD 21702

The following individual shall be the TPOC for this task order:

Sharon Bargo

Technical Laboratory Manager

Laboratory of Integrative Cancer Immunology

National Institutes of Health (NIH)

37 Convent Drive

Bldg.37 / Room 4140

Bethesda, MD 20892

Performance of work under this Purchase Order must be subject to the technical direction of the

COR/TPOC identified above. The term "technical direction" includes direction to the Contractor that fills in details and otherwise serves to ensure that tasks outlined in this requirements document are accomplished satisfactorily. Technical direction must be within the scope of this requirements document.

The COR/TPOC does not have authority to issue technical direction that:

a. Constitutes a change of assignment or additional work outside of this requirements document

b. Constitutes a change as defined in the clause 52.212-4 (c) governing "Changes";

c. In any manner causes an increase or decrease in the contract price, or the time required for contract performance;

d. Change any of the terms, conditions, or requirements of the contract;

e. Interferes with the Contractor's right to perform under the terms and conditions of the contract; or

f. Directs, supervises, or otherwise controls the actions of the Contractor's employees.

Technical direction may be oral or in writing. The COR/TPOC shall confirm oral direction in writing within five business days, with a copy to the Contracting Officer. The Contractor shall proceed promptly with performance resulting from the technical direction issued by the COR/TPOC. If, in the opinion of the Contractor, any direction of the COR/TPOC, or their designee, falls within the limitations in (b), above, the Contractor shall immediately notify the Contracting Officer no later than the beginning of the next Government business day.

Failure of the Contractor and the Contracting Officer to agree that technical direction is within the scope of the contract shall be subject to the terms of the clause 52.212-4 (e) titled "Disputes."

9.0 DELIVERABLE SCHEDULE

The Contractor shall submit deliverables as follows:

Deliverable Quantity Delivery

Schedule

Deliver to

(1) Complete the production of viral vectors

1 Due three months from date of award.

Contracting Officers

Representative/Technical Point of

Contact via email in electronic format.

Deliverable Quantity Delivery

Schedule

Deliver to

(2) Final Report 1 Due on or before end date of the period of performance.

Contracting Officers

Representative/Technical Point of

Contact via email in electronic format.

10.0 PAYMENT

Payment under the award will be made on a Firm Fixed Price (FFP) basis, in accordance with the pricing established at the time of award. Payment is contingent upon the successful submission and acceptance of each deliverable identified in the Deliverables Schedule (Section 9) of this Statement of Work.

Payment Terms:

The Contractor shall submit each deliverable in accordance with the due dates and format specified in

Section 9, Deliverables Schedule.

The Contracting Officer's Representative (COR) will review each submitted deliverable to determine whether it meets the requirements of this Statement of Work.

Upon written approval of a deliverable by the COR, the Contractor may submit an invoice for the amount associated with that deliverable.

Payment authorization requires submission and approval of invoices to the COR and NIH OFM, in accordance with the payment provisions/clauses listed in the contract. If a deliverable is rejected, the

Contractor shall correct and resubmit the deliverable within the timeframe specified by the COR.

Payment will not be issued until the resubmitted deliverable is approved.

Final payment will be made upon submission and approval of the final deliverable, in accordance with the

Period of Performance established under this award.

Invoices shall be submitted in accordance with the instructions provided in this Purchase Order and shall refer to the applicable deliverable(s) for which payment is being requested.